

We Claim:

1. A method of detecting the presence of a target BL172 polynucleotide in a test sample, comprising:
 - (a) contacting said test sample with at least one BL172-specific polynucleotide or complement thereof; and
 - (b) detecting the presence of said target BL172 polynucleotide in the test sample, wherein said BL172-specific polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, and fragments or complements thereof.
2. The method of claim 1, wherein said target BL172 polynucleotide is attached to a solid phase prior to performing step (a).
3. A method for detecting mRNA of BL172 in a test sample, comprising:
 - (a) performing reverse transcription with at least one primer in order to produce cDNA;
 - (b) amplifying the cDNA obtained from step (a) using BL172 oligonucleotides as sense and antisense primers to obtain BL172 amplicon; and
 - (c) detecting the presence of said BL172 amplicon, wherein the BL172 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, and fragments or complements thereof.
4. The method of claim 3, wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).
5. The method of claim 3, wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.
6. A method of detecting a target BL172 polynucleotide in a test sample suspected of containing said target, comprising:

- (a) contacting said test sample with at least one BL172 oligonucleotide as a sense primer and with at least one BL172 oligonucleotide as an anti-sense primer and amplifying to obtain a first stage reaction product;
- (b) contacting said first stage reaction product with at least one other BL172 oligonucleotide to obtain a second stage reaction product, with the proviso that the other BL172 oligonucleotide is located 3' to the BL172 oligonucleotides utilized in step (a) and is complementary to said first stage reaction product; and
- (c) detecting said second stage reaction product as an indication of the presence of the target BL172 polynucleotide, wherein the BL172 oligonucleotides utilized in steps (a) and (b) have at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, and fragments or complements thereof.
7. The method of claim 6, wherein said test sample is reacted with a solid phase prior to performing one of steps (a), (b), or (c).
8. The method of claim 6, wherein said detection step comprises utilizing a detectable label capable of generating a measurable signal.
9. The method of claim 8, wherein said detectable label is reacted to a solid phase.
10. A test kit useful for detecting BL172 polynucleotide in a test sample, comprising a container containing at least one BL172 polynucleotide having at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO-3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, and fragments or complements thereof.
11. A purified polynucleotide or fragment thereof derived from a BL172 gene, wherein said polynucleotide is capable of selectively hybridizing to the nucleic acid of said BL172 gene and has at least 50% identity with a polynucleotide selected from the group consisting of (a) SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 4, SEQUENCE ID NO 5, complements thereof, and (b) fragments of SEQUENCE ID NO 1, SEQUENCE ID NO 2, and SEQUENCE ID NO 3.

12. The purified polynucleotide of claim 11, wherein said polynucleotide is produced by recombinant techniques.

5 13. The purified polynucleotide of claim 11, wherein said polynucleotide is produced by synthetic techniques.

14. The purified polynucleotide of claim 11, wherein said polynucleotide comprises a sequence encoding at least one BL172 epitope.
10

15. A recombinant expression system comprising a nucleic acid sequence that includes an open reading frame derived from BL172 operably linked to a control sequence compatible with a desired host, wherein said nucleic acid sequence has at least 50% identity with a polynucleotide selected from the group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, and fragments or complements thereof.
15

16. A cell transfected with the recombinant expression system of claim 15.
20

17. A BL172 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.
25

18. The polypeptide of claim 17, wherein said polypeptide is produced by recombinant techniques.

30 19. The polypeptide of claim 17, wherein said polypeptide is produced by synthetic techniques.

20. An antibody which specifically binds to at least one BL172 epitope, wherein said BL172 epitope is derived from an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.
35

21. An assay kit for determining the presence of BL172 antigen or anti-BL172 antibody in a test sample, comprising a container containing a BL172 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.

22. The assay kit of claim 21, wherein said polypeptide is attached to a solid phase.

23. An assay kit for determining the presence of BL172 antigen in a test sample, comprising a container containing an antibody which specifically binds to a BL172 antigen which comprises at least one BL172 epitope.

24. The kit of claim 23, wherein said antibody is attached to a solid phase.

25. A method for producing a polypeptide comprising at least one BL172 epitope, said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 50% identity to an amino acid sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.

26. A method for detecting BL172 antigen in a test sample suspected of containing said BL172 antigen, comprising:

(a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one epitope of a BL172 antigen selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof, wherein said contacting is carried out for a time and under conditions sufficient for the formation of antibody/antigen complexes; and

(b) detecting the presence of said complexes as an indication of the presence of said BL172 antigen.

27. The method of claim 26, wherein said antibody is attached to a solid phase.

28. A method for detecting the presence of antibodies specific for a BL172 antigen in a test sample suspected of containing such antibodies, said method comprising:

- 5 (a) contacting the test sample with a BL172 polypeptide, wherein said BL172 polypeptide contains at least one BL172 epitope derived from an amino acid sequence or fragment thereof having at least 50% identity to an amino acid sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof, and further wherein said contacting is carried out for a
10 time and under conditions sufficient to allow antigen/antibody complexes to form; and
- (b) detecting the presence of said complexes as an indication of the presence of said antibodies specific for a BL172 antigen.

15 29. The method of claim 28, wherein said BL172 polypeptide is attached to a solid phase.

30. A cell transfected with a nucleic acid sequence encoding at least one BL172 epitope, wherein said nucleic acid sequence is selected from the
20 group consisting of SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 3, SEQUENCE ID NO 4, SEQUENCE ID NO 5, and fragments or complements thereof.

31. A method for producing antibodies which specifically bind to
25 BL172 antigen, comprising administering to an individual an isolated immunogenic polypeptide or fragment thereof in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide comprises at least one BL172 epitope and has at least 50% identity to a sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18,
30 SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.

32. A method for producing antibodies which specifically bind to BL172 antigen, comprising administering to an individual a plasmid comprising a sequence which encodes at least one BL172 epitope derived from a
35 polypeptide having an amino acid sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.

33. A composition of matter comprising a BL172 polynucleotide or fragment thereof, wherein said polynucleotide has at least 50% identity with a polynucleotide selected from the group consisting of (a) SEQUENCE ID NO 1, SEQUENCE ID NO 2, SEQUENCE ID NO 4, SEQUENCE ID NO 5,
5 complements thereof, and (b) fragments of SEQUENCE ID NO 1, SEQUENCE ID NO 2, and SEQUENCE ID NO 3.

34. A composition of matter comprising a polypeptide containing at least one BL172 epitope, wherein said polypeptide has at least 50% identity with
10 a sequence selected from the group consisting of SEQUENCE ID NO 17, SEQUENCE ID NO 18, SEQUENCE ID NO 19, SEQUENCE ID NO 20, and fragments thereof.

35. The test kit of claim 10 further comprising a container with tools
15 useful for collection of said sample, wherein the tools are selected from the group consisting of lancets, absorbent paper, cloth, swabs and cups.

36. The assay kit of claim 21 further comprising a container with tools useful for collection of said sample, wherein the tools are selected from the
20 group consisting of lancets, absorbent paper, cloth, swabs and cups.

37. The test kit of claim 23 further comprising a container with tools useful for collection of said sample, wherein the tools are selected from the group consisting of lancets, absorbent paper, cloth, swabs and cups.
25

38. A gene, or fragment thereof, which codes for a BL172 protein which comprises an amino acid sequence with at least 50% identity to SEQUENCE ID NO 17.

39. A gene, or fragment thereof, comprising DNA having at least
30 50% identity with SEQUENCE ID NO 4 or SEQUENCE ID NO 5.

40. The method of claim 1 wherein presence of said target BL172 polynucleotide in said test sample is indicative of urinary tract disease.
35

41. The method of claim 3 wherein presence of said amplicon is indicative of urinary tract disease.

42. The method of claim 6 wherein presence of said second stage reaction product is indicative of urinary tract disease.

43. The method of claim 26 wherein detection of said complexes is
5 indicative of urinary tract disease.

44. The method of claim 28 wherein detection of said complexes is indicative of urinary tract disease.